Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Mark Stephen Huberman, M.D.

TitleAssistant Professor of Medicine
InstitutionBeth Israel Deaconess Medical Center
DepartmentMedicine
AddressBeth Israel Deaconess Med Ctr
Shapiro Clinical Ctr, 913
330 Brookline Ave
Boston MA 02215
Phone617/667-9236
Fax617/975-5665

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB. Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer. Sci Transl Med. 2013 Dec 18; 5(216):216ra177.
    View in: PubMed
  2. Folch E, Yamaguchi N, Vanderlaan PA, Kocher ON, Boucher DH, Goldstein MA, Huberman MS, Kent MS, Gangadharan SP, Costa DB, Majid A. Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer. J Thorac Oncol. 2013 Nov; 8(11):1438-44.
    View in: PubMed
  3. Yamaguchi N, Vanderlaan PA, Folch E, Boucher DH, Canepa HM, Kent MS, Gangadharan SP, Majid A, Kocher ON, Goldstein MA, Huberman MS, Costa DB. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. Lung Cancer. 2013 Oct; 82(1):31-7.
    View in: PubMed
  4. Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, Harper H, Huberman M, Ramalingam S, Wong KK, Teofilovici F, Guo W, Shapiro GI. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013 Jun 1; 19(11):3068-77.
    View in: PubMed
  5. Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, Goldstein MA, Huberman MS, Costa DB. Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol. 2013 Jan; 8(1):45-51.
    View in: PubMed
  6. Nguyen KS, Sanford RA, Huberman MS, Goldstein MA, McDonald DM, Farquhar M, Gangadharan SP, Kent MS, Michaud G, Majid A, Berman SM, Aronovitz JA, Nedea EA, Boiselle PM, Cohen DW, Kobayashi S, Costa DB. Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center. J Oncol Pract. 2012 Jan; 8(1):57-62.
    View in: PubMed
  7. Britt GJ, Gaughan EM, Nguyen KS, Warner JL, Goldstein MA, Huberman MS, Costa DB. Case series of treatment approaches in fit nonagenarians with stage IV non-small-cell lung cancer. J Thorac Dis. 2011 Jun; 3(2):141-3.
    View in: PubMed
  8. Neal JW, Heist RS, Fidias P, Temel JS, Huberman M, Marcoux JP, Muzikansky A, Lynch TJ, Sequist LV. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Thorac Oncol. 2010 Nov; 5(11):1855-8.
    View in: PubMed
  9. Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol. 2010 Jul; 5(7):1048-53.
    View in: PubMed
  10. Sequist LV, Fidias PM, Temel JS, Kolevska T, Rabin MS, Boccia RV, Burris HA, Belt RJ, Huberman MS, Melnyk O, Mills GM, Englund CW, Caldwell DC, Keck JG, Meng L, Jones M, Brown GL, Edelman MJ, Lynch TJ. Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer. J Thorac Oncol. 2009 Nov; 4(11):1389-96.
    View in: PubMed
  11. Ye C, Masterman JR, Huberman MS, Gangadharan SP, McDonald DC, Kent MS, DeCamp MM. Subdivision of the T1 size descriptor for stage I non-small cell lung cancer has prognostic value: a single institution experience. Chest. 2009 Sep; 136(3):710-5.
    View in: PubMed
  12. Wong ET, Huberman M, Lu XQ, Mahadevan A. Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol. 2008 Dec 1; 26(34):5649-50.
    View in: PubMed
  13. Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Jänne PA, Huberman MS, Pao W, Tenen DG, Kobayashi S. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 2008 Nov 1; 14(21):7060-7.
    View in: PubMed
  14. Heist RS, Fidias P, Huberman M, Ardman B, Sequist LV, Temel JS, Lynch TJ. A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. J Thorac Oncol. 2008 Oct; 3(10):1153-8.
    View in: PubMed
  15. Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007 Oct; 4(10):1669-79; discussion 1680.
    View in: PubMed
  16. Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer. 2007 Oct; 58(1):95-103.
    View in: PubMed
  17. Dragovich T, Huberman M, Von Hoff DD, Rowinsky EK, Nadler P, Wood D, Hamilton M, Hage G, Wolf J, Patnaik A. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol. 2007 Jul; 60(2):295-303.
    View in: PubMed
  18. Lam P, Berman S, Thurer R, Ashiku S, DeCamp M, Goldstein M, Schumer S, Halmos B, Karp D, Coute D, Bergman M, Boyd-Sirard C, Ou SH, Muzikansky A, Woodard C, Huberman M. Phase II trial of sequential chemotherapy followed by chemoradiation, surgery, and postoperative chemotherapy for the treatment of stage IIIA/IIIB non-small-cell lung cancer. Clin Lung Cancer. 2006 Sep; 8(2):122-9.
    View in: PubMed
  19. Costa DB, Huberman MS. Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib. Diabetes Care. 2006 Jul; 29(7):1711.
    View in: PubMed
  20. Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006 Jul 1; 12(13):3908-14.
    View in: PubMed
  21. Mayer S, Cypess AM, Kocher ON, Berman SM, Huberman MS, Hartzband PI, Halmos B. Uncommon presentations of some common malignancies: Case 1. Sequential paraneoplastic endocrine syndromes in small-cell lung cancer. J Clin Oncol. 2005 Feb 20; 23(6):1312-4.
    View in: PubMed
  22. Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol. 2004 Aug 15; 22(16):3238-47.
    View in: PubMed
  23. Petrovich Z, Lieskovsky G, Stein JP, Huberman M, Skinner DG. Comparison of surgery alone with surgery and adjuvant radiotherapy for pT3N0 prostate cancer. BJU Int. 2002 Apr; 89(6):604-11.
    View in: PubMed
  24. Petrovich Z, Lieskovsky G, Langholz B, Huberman M, Streeter O, Skinner DG. Nonrandomized comparison of surgery with and without adjuvant pelvic irradiation for patients with pT3N0 adenocarcinoma of the prostate. Am J Clin Oncol. 2001 Dec; 24(6):537-46.
    View in: PubMed
  25. Boiselle PM, Morrin MM, Huberman MS. Gemcitabine pulmonary toxicity: CT features. J Comput Assist Tomogr. 2000 Nov-Dec; 24(6):977-80.
    View in: PubMed
  26. Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C, Berecz G. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol. 2000 Nov-Dec; 23(6):324-30.
    View in: PubMed
  27. Vakil E, Kahan S, Huberman M, Osimani A. Motor and non-motor sequence learning in patients with basal ganglia lesions: the case of serial reaction time (SRT). Neuropsychologia. 2000; 38(1):1-10.
    View in: PubMed
  28. Stram DO, Langholz B, Huberman M, Thomas DC. Correcting for exposure measurement error in a reanalysis of lung cancer mortality for the Colorado Plateau Uranium Miners cohort. Health Phys. 1999 Sep; 77(3):265-75.
    View in: PubMed
  29. Sanz-Altamira PM, Ferrante K, Jenkins RL, Lewis WD, Huberman MS, Stuart KE. A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer. 1998 Jun 15; 82(12):2321-5.
    View in: PubMed
  30. Sanz-Altamira PM, Spence LD, Huberman MS, Posner MR, Steele G, Perry LJ, Stuart KE. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. Dis Colon Rectum. 1997 Jul; 40(7):770-5.
    View in: PubMed
  31. Eder JP, Rubin E, Stone R, Bryant M, Xu G, Supko J, Kinchla N, Lynch T, Hurwitz S, Rodriguez D, Shapiro C, Toppmeyer D, Grossbard M, Vosburg E, Huberman M, Schnipper L, Shulman L, Kufe DW. Trials of 9-amino-20(S)-camptothecin in Boston. Ann N Y Acad Sci. 1996 Dec 13; 803:247-55.
    View in: PubMed
  32. Stuart K, Tessitore J, Huberman M. 5-Fluorouracil and alpha-interferon in hepatocellular carcinoma. Am J Clin Oncol. 1996 Apr; 19(2):136-9.
    View in: PubMed
  33. Anand A, Huberman M. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer. 1995 Sep 1; 76(5):916-7.
    View in: PubMed
  34. Stuart K, Posner M, Campbell K, Huberman M. Cisplatin and chronic oral etoposide as salvage therapy for advanced colorectal carcinoma. Am J Clin Oncol. 1995 Aug; 18(4):300-2.
    View in: PubMed
  35. Posner MR, Bleday R, Huberman M, Jessup JM, Busse P, Steele G. Impact of combined modality therapy on the treatment of adenocarcinoma of the colon. Semin Surg Oncol. 1993 Jan-Feb; 9(1):33-8.
    View in: PubMed
  36. Jessup JM, Posner M, Huberman M. Influence of multimodality therapy on the management of pancreas carcinoma. Semin Surg Oncol. 1993 Jan-Feb; 9(1):27-32.
    View in: PubMed
  37. Jessup JM, Posner M, Huberman M, LoCicero J, Stone M, Steele G. Efficacy of multimodality therapy in gastric adenocarcinoma. Semin Surg Oncol. 1993 Jan-Feb; 9(1):19-26.
    View in: PubMed
  38. Eyre RC, Huberman MS, Balogh K. Non-Hodgkin's lymphoma of the kidney with inferior vena caval extension. Urol Int. 1993; 51(1):43-5.
    View in: PubMed
  39. Huberman M, Bering H, Fallon B, Tessitore J, Sonnenborn H, Paul S, Zeffren J, Levitt D, Groopman J. A phase I study of an outpatient regimen of recombinant human interleukin-2 and alpha-2a-interferon in patients with solid tumors. Cancer. 1991 Oct 15; 68(8):1708-13.
    View in: PubMed
  40. Steele G, Busse P, Huberman MS, LeClair JM, Falchuk ZM, Mayer RJ, Bothe A, Ravikumar TS, Stone M, Jessup JM. A pilot study of sphincter-sparing management of adenocarcinoma of the rectum. Arch Surg. 1991 Jun; 126(6):696-701; discussion 701-2.
    View in: PubMed
  41. Mittelman A, Huberman M, Puccio C, Fallon B, Tessitore J, Savona S, Eyre R, Gafney E, Wick M, Skelos A, et al. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma. Cancer. 1990 Aug 15; 66(4):664-9.
    View in: PubMed
  42. Cohen MC, Huberman MS, Nesto RW. Interferon alfa-induced cardiac dysfunction. N Engl J Med. 1990 May 17; 322(20):1469.
    View in: PubMed
  43. Bern MM, Lokich JJ, Wallach SR, Bothe A, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med. 1990 Mar 15; 112(6):423-8.
    View in: PubMed
  44. Cohen MC, Huberman MS, Nesto RW. Recombinant alpha 2 interferon-related cardiomyopathy. Am J Med. 1988 Oct; 85(4):549-51.
    View in: PubMed
  45. Bern MM, Wallach SR, Arkin CF, Lokich JJ, Huberman MS, Anderson NR, Corkery JC, Paul SD, Phillips DF, Sonneborn HA, et al. Etoposide in combination with cytarabine, doxorubicin, and 6-thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age. Cancer Treat Rep. 1987 Feb; 71(2):201-3.
    View in: PubMed
  46. Huberman M, Lokich J, Greene R, Paul S, Phillips D, Sonneborn H, Zipoli T. Vinblastine plus cisplatin in advanced non-small cell lung cancer: lack of advantage for vinblastine infusion schedule. Cancer Treat Rep. 1986 Feb; 70(2):287-9.
    View in: PubMed
  47. Huberman MS, Lokich JJ, Hill T, Kaldany A, Kassis A, Price T, Moore C, Davis S, Kasulis P, Monaco AP, et al. Non-human primate (baboon) anti-carcinoembryonic antigen antibody infusion in patients with metastatic adenocarcinoma. A phase I study. Cancer Immunol Immunother. 1986; 23(2):137-42.
    View in: PubMed
  48. Matelski H, Greene R, Huberman M, Lokich J, Zipoli T. Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer. Am J Clin Oncol. 1985 Apr; 8(2):128-33.
    View in: PubMed
  49. Groopman JE, Sarngadharan MG, Salahuddin SZ, Buxbaum R, Huberman MS, Kinniburgh J, Sliski A, McLane MF, Essex M, Gallo RC. Apparent transmission of human T-cell leukemia virus type III to a heterosexual woman with the acquired immunodeficiency syndrome. Ann Intern Med. 1985 Jan; 102(1):63-6.
    View in: PubMed
  50. Matelski HW, Lokich JJ, Huberman MS, Zipoli TE, Paul S, Sonneborn H, Philips D. Adriamycin, cyclophosphamide, and etoposide (VP-16-213) in extensive-stage small cell lung cancer. Am J Clin Oncol. 1984 Dec; 7(6):729-32.
    View in: PubMed
  51. Huberman MS. Comparison of systemic chemotherapy with hepatic arterial infusion in metastatic colorectal carcinoma. Semin Oncol. 1983 Jun; 10(2):238-48.
    View in: PubMed
  52. Levenson RM, Ihde DC, Huberman MS, Cohen MH, Bunn PA, Minna JD. Phase II trial of cisplatin in small cell carcinoma of the lung. Cancer Treat Rep. 1981 Sep-Oct; 65(9-10):905-7.
    View in: PubMed
  53. Bunn PA, Huberman MS, Whang-Peng J, Schechter GP, Guccion JG, Matthews MJ, Gazdar AF, Dunnick NR, Fischmann AB, Ihde DC, Cohen MH, Fossieck B, Minna JD. Prospective staging evaluation of patients with cutaneous T-cell lymphomas. Demonstration of a high frequency of extracutaneous dissemination. Ann Intern Med. 1980 Aug; 93(2):223-30.
    View in: PubMed
  54. Huberman MS, Bunn PA, Matthews MJ, Ihde DC, Gazdar AF, Cohen MH, Minna JD. Hepatic involvement in the cutaneous T-cell lymphomas: results of percutaneous biopsy and peritoneoscopy. Cancer. 1980 Apr 1; 45(7):1683-8.
    View in: PubMed
  55. Huberman M, Fossieck BE, Bunn PA, Cohen MH, Ihde DC, Minna JD. Herpes zoster and small cell bronchogenic carcinoma. Am J Med. 1980 Feb; 68(2):214-8.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Huberman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_